Sustainability | April 17, 2025
Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Strengthening capabilities in Peptide Therapeutics and CDMO services
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Raichur site is the group’s largest API facility and part of a wider network of seven sites
Asahi Kasei Life Science covers a broad range of bioprocess products and services
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subscribe To Our Newsletter & Stay Updated
